Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies.

Sethi TK, Basdag B, Bhatia N, Moslehi J, Reddy NM
Curr Hematol Malig Rep. 2017 12 (3): 257-267

PMID: 28233150 · DOI:10.1007/s11899-017-0369-y

Advances in drug discovery have led to the use of effective targeted agents in the treatment of hematologic malignancies. Drugs such as proteasome inhibitors in multiple myeloma and tyrosine kinase inhibitors in chronic myeloid leukemia and non-Hodgkin lymphoma have changed the face of treatment of hematologic malignancies. There are several reports of cardiovascular adverse events related to these newer agents. Both "on-target" and "off-target" effects of these agents can cause organ-specific toxicity. The need for long-term administration for most of these agents requires continued monitoring of toxicity. Moreover, the patient population is older, often over 50 years of age, making them more susceptible to cardiovascular side effects. Additional factors such as prior exposure to anthracyclines often add to this toxicity. In light of their success and widespread use, it is important to recognize and manage the unique side effect profile of targeted agents used in hematologic malignancies. In this article, we review the current data for the incidence of cardiovascular side effects of targeted agents in hematologic malignancies and discuss a preemptive approach towards managing these toxicities.

MeSH Terms (11)

Animals Anthracyclines Antineoplastic Agents Cardiotoxicity Cardiovascular Diseases Disease Management Drug Evaluation, Preclinical Hematologic Neoplasms Humans Molecular Targeted Therapy Protein Kinase Inhibitors

Connections (1)

This publication is referenced by other Labnodes entities: